Nine Ten Capital Management LLC Has $79.43 Million Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Nine Ten Capital Management LLC cut its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,605,604 shares of the company's stock after selling 721,194 shares during the period. Cellebrite DI accounts for 22.7% of Nine Ten Capital Management LLC's investment portfolio, making the stock its largest holding. Nine Ten Capital Management LLC owned about 1.75% of Cellebrite DI worth $79,431,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in CLBT. NewEdge Advisors LLC grew its stake in Cellebrite DI by 600.7% during the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after purchasing an additional 3,352 shares during the period. R Squared Ltd bought a new position in shares of Cellebrite DI during the 4th quarter worth approximately $100,000. Polen Capital Management LLC bought a new stake in shares of Cellebrite DI in the 4th quarter valued at $222,000. Victory Capital Management Inc. acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $234,000. Finally, HighTower Advisors LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at $274,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT traded up $0.67 during midday trading on Wednesday, hitting $19.06. 849,431 shares of the company's stock were exchanged, compared to its average volume of 1,407,376. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30. The company has a market cap of $4.56 billion, a PE ratio of -13.71, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The stock has a 50 day moving average price of $18.79 and a 200-day moving average price of $20.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. upped their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.